D elirium in critical illness has been linked to increased morbidity, mortality, and long-term cognitive impairment (1) (2) (3) . The pathophysiology of delirium remains incompletely understood and involves a complex interplay between predisposing and precipitating influences (4) . It is important to identify strategies to prevent delirium by focusing on specific modifiable risk factors. There is published evidence in the adult critical care literature establishing that sedatives-particularly benzodiazepines-contribute to the development of delirium (5) (6) (7) . However, such evidence is lacking in the PICU population, and benzodiazepines remain a first-line therapy for sedation in most PICUs (8) . This represents a possible modifiable risk factor, as there are alternative sedative medications (albeit with other potential side effects) available for use in PICU patients (9) .
Recent pediatric delirium studies have shown an association between benzodiazepine exposure and delirium (10-12) but fall short of establishing that benzodiazepines directly contribute to delirium development in children. It is important to assess for a temporal relationship before assuming a causal role. For example, a child may be prescribed benzodiazepines as a treatment for the symptoms of agitated delirium. Furthermore, there is an intricate relationship among benzodiazepine use, opiate use, mechanical ventilation, and delirium in the PICU. It is important to obtain an unbiased assessment of the relationship between benzodiazepines and next day delirium, as standard approaches to confounding may be biased by exposure to time-dependent covariates (13) .
We designed this study to clarify the relationship between benzodiazepines and pediatric delirium. We hypothesized that there was an independent, temporal relationship between receipt of benzodiazepines and subsequent development of delirium in children, after controlling for time-dependent covariates. We further hypothesized that there was an association between dose of benzodiazepines administered and next day diagnosis of delirium.
MATERIALS AND METHODS
Our study was conducted with approval from the Institutional Review Board at New York Presbyterian Hospital Weill Cornell Medical Center. All patients admitted consecutively to our academic, urban, tertiary care PICU from January 2015 to June 2015 were included. This group is a part of a larger cohort of children included in a 12-month dataset. Children were prospectively screened for delirium each day throughout their PICU stay using the Cornell Assessment for Pediatric Delirium (CAPD). Each child was assigned a daily cognitive status of delirium, coma, or normal (i.e., delirium free and coma free). A status of "delirium" was defined as a positive CAPD screen with diagnosis confirmed by the treating physician. A status of "coma" was defined as being unarousable to verbal stimulation. A status of "normal" was defined as a negative CAPD screen. This cohort was included in a prior publication describing the epidemiology and outcomes of pediatric delirium (11) .
We reviewed the electronic medical record of enrolled patients to determine, in granular detail, the total dose of benzodiazepines and/or opiates each child received on a daily basis throughout the PICU stay. For benzodiazepines, we collected doses of lorazepam, midazolam, clonazepam, and diazepam. For opiates, we collected doses of fentanyl, hydromorphone, morphine, and oxycodone. We then converted all benzodiazepine medications to midazolam equivalents in mg/kg/d (14) . We converted all opiate medications to fentanyl equivalents in μg/kg/d (15) . A "transition to delirium" was defined as a child who transitioned from normal status 1 day to delirious status the next day. All data regarding benzodiazepine and opiate exposure timing and dosing presented in this article are novel and have never been published before.
Based on extensive review of the adult and pediatric literature, we determined a priori that other variables that might predict transition to delirium would include prior delirium (adult studies have shown that the strongest predictor of delirium in adults is delirium on the day prior), mechanical ventilation, and receipt of opiates (5, 7, (9) (10) (11) 16) .
Patient demographic and clinical characteristics as well as specific PICU characteristics were described as n (%) for categorical measures or as mean, sd, median, and spread for continuous measures. Pearson's chi-square/Fisher exact tests were used to explore the associations of day prior variables of interest and delirium. A multivariable mixed effects model was constructed to predict delirium by benzodiazepine exposure on the day prior to evaluation (yes/no), controlling for opiate exposure day prior (yes/no), cognitive status day prior (normal, comatose, or delirious), and mechanical ventilation (yes/ no). To assess for temporality, a multivariable mixed effects model was then constructed to predict transition to delirium (i.e., delirium development after a normal day) by benzodiazepine exposure on the day prior to evaluation, while controlling for opiate exposure day prior and mechanical ventilation.
To minimize time-varying confounding, we then used a marginal structural model (MSM). MSM allows for use of observational data in estimating causal effects of given exposures that vary with time (13) . For example, a child who requires intubation is often sedated with opiates and benzodiazepines and is likely to be delirious. As noted by Pisani et al (17) in their assessment of haloperidol and its effect on next day delirium, MSM creates a pseudorandomized sample with a main outcome model (likelihood of next day delirium, conditional on current day's interventions) that has less timevarying confounding. We first constructed a weight model to calculate the probability of benzodiazepine exposure, adjusted for respective time-varying confounders (determined a priori) on the current day and prior day ( Fig. 1) . Confounders in the weight model included opiate exposure, receipt of mechanical ventilation, cognitive status, and benzodiazepine exposure. Stabilized inverse probability of treatment weights as defined by Robins et al (13) were obtained from the weight model and assessed for outliers. A subsequent logistic generalized estimating equation was constructed employing the weights, and an adjusted odds ratio (OR) was obtained to assess the independent effect of benzodiazepine exposure on next day delirium.
To assess for dose response, a univariate mixed effects model was constructed to predict delirium by benzodiazepine dose received on the prior day, controlling for opiates and mechanical ventilation on that day. Midazolam and fentanyl equivalents were log transformed for modeling, and the predicted probability of delirium development was plotted to visualize the dose-response relationship. All tests were two sided with statistical significance evaluated at the 0.05 α level. Analyses were performed in R Versions 3.4.0 and 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS

Descriptives
Between January 2015 and June 2015, there were 580 consecutive admissions with a median PICU length of stay of 3 days. Table 1 shows the demographics of our study population. Two-thousand two-hundred ninety-one PICU days were captured in this study. Children received benzodiazepines on 651 days (28% of total PICU days) and opiates on 1,017 days (44%). Children required invasive mechanical ventilation for 693 days (30% of total PICU days).
Children were diagnosed with delirium on 487 of the 2,291 days (21%) and in coma for 237 days (10%; almost all due to deep pharmacologic sedation). For 68% of the days in the PICU, children were classified as having a normal mental status (1,567 d). With respect to delirium subtypes, of the 487 days with delirium, hypoactive delirium was most common (255 d; 52%). The next most common subtype was mixed delirium (191 d; 39%), followed by hyperactive delirium (only 41 d; 8%).
Predictors of Delirium
In bivariate analyses, we found that highly significant predictors of delirium in our sample included being delirious the day prior (65% vs 27%; p < 0.001), receipt of benzodiazepines the day prior (38% vs 14%; p < 0.001), receipt of opiates the day (Table 2) determined that the strongest predictor of delirium was being delirious on the day prior, with an OR of 8.2 (CI, 5.7-11.7; p < 0.001). Even after controlling for prior delirium status, receipt of benzodiazepines more than doubled a child's chance of being delirious on the following day (OR, 2.0; CI, 1.4-2.9; p < 0.001). As expected, need for invasive mechanical ventilation was highly and independently associated with delirium (OR, 3.9; CI, 2.6-5.9; p < 0.001). Interestingly, opiate exposure was not independently associated with delirium.
Temporal Relationship
As prior delirium was the strongest predictor of subsequent delirium, we then performed a subgroup analysis to include only days with normal cognitive status (i.e., when benzodiazepines were administered to children who were not already delirious) (n = 1,540 d). This would allow determination of the effect of benzodiazepines on subsequent development of delirium. Benzodiazepines were highly and independently associated with transition from normal mental status to delirium, more than quadrupling delirium rates (OR, 4.4; CI, 1.7-11; p = 0.002), when compared with a child with a normal cognitive status who did not receive benzodiazepines (Fig. 2) . We again noted that opiates did not prove to be a statistically significant predictor of transition to delirium. The MSM created a pseudorandomized sample, accounting for prior cognitive status, need for mechanical ventilation, and receipt of opiates when assessing the effect of benzodiazepines on subsequent delirium. This allowed for inclusion of children who were already delirious on the day when benzodiazepines were administered. The MSM (n = 2,291 d) demonstrated that benzodiazepines independently increased subsequent delirium risk by 333% (OR, 3.33; CI, 1.43-7.80) ( Table 2 ).
Dose-Response Effect
A univariate model assessed the dose-response relationship between benzodiazepines (received on a day with normal cognitive status) and delirium development. It showed that for every one log increase in benzodiazepine dose administered, there was a 43% increase in the risk for next day transition to delirium (OR, 1.43; CI, 1.26-1.63; p < 0.001). Figure 3 shows a graphical representation of benzodiazepine dosage, displaying that a child's probability of transitioning to delirium increases drastically with increasing exposure. Even after controlling for receipt of opiates and mechanical ventilation, benzodiazepine dosage remained a significant predictor of transition to delirium (OR, 1.25; CI, 1.09-1.43; p = 0.002).
DISCUSSION
Many studies in critically ill adults have shown a strong and independent relationship between benzodiazepines and delirium (7, (18) (19) (20) . As a result, there has been a paradigm shift in adult critical care such that benzodiazepines are avoided in most patients (1, 21) . However, in pediatric critical care units, benzodiazepines remain the first-line sedative choice (10) .
This study is one of the first of its kind in pediatric critical care. Similar to the adult literature (7, 18, 20) , we have shown that benzodiazepines are an independent predictor of subsequent delirium in critically ill children after controlling for multiple confounders including cognitive status. We have carefully structured a pseudorandomized sample to control for time-varying confounders which demonstrated that benzodiazepines are temporally related to delirium (OR, 3.3) and demonstrated an even stronger effect when benzodiazepines are given to children who are not yet delirious (OR, 4.4). In the absence of a randomized controlled trial, these methods provide evidence for a causal interpretation of these observational data.
Furthermore, we have shown a robust relationship between benzodiazepine dosage and predicted probability of delirium development. This is consistent with a recent pediatric study that showed an association between benzodiazepine dose and delirium risk and between benzodiazepines and prolonged PICU stay (12) .
Another important point to note is that opiate exposure was not independently associated with delirium. This may support the use of an "analgosedation" approach in critically ill children. Endorsed by the Society of Critical Care Medicine for use in adults, analgosedation recommends an analgesic first approach to critically ill patients, with optimization of pain control (using both nonopioid and opioid analgesics and taking advantage of the sedative side effects of the opiates), with minimization of additional sedation (1, (21) (22) (23) . Less sedation should improve recognition of pain and optimize pain management. With better pain control, there is less need for sedation. With less sedation, there is less delirium and more opportunity for mobilization and weaning of mechanical ventilation. This paradigm shift has proven to be quite effective in changing the landscape in adult critical care (24, 25) . It is our hope that as similar data emerge in critically ill children, a comparable culture shift will take place (26) .
This study has noteworthy strengths, including a large sample size, prospective assessment of daily cognitive status, granular data collection regarding medication exposure, and sophisticated statistical analyses that allow for control of timedependent covariates. There are also important limitations. As a single-center study, these findings may not be widely generalizable, and it will be important to replicate these findings in other institutions. Also, there are additional medications that may contribute to delirium, such as anticholinergics and steroids, which have not been included in this study design. Further research is needed to assess the relationship between delirium and these (and other) drug classes. We acknowledge the limitations of not accounting for all time-varying confounders, as well as not being able to account for unmeasured confounding. Finally, as an observational study, we must be cautious not to overconclude (particularly with respect to the lack of independent opiate effect on delirium development; it is possible that the vast effect of benzodiazepines overshadowed an opiate component). Further multi-institutional interventional studies (perhaps comparing benzodiazepine-based sedation regimens to a benzodiazepine-sparing sedation approach) may be warranted.
CONCLUSIONS
In this study, we have shown an independent, temporal, and dose-response relationship between benzodiazepine exposure and subsequent pediatric delirium. With alternate sedation choices available, this is an important and modifiable risk factor. Adoption of a benzodiazepine-sparing approach in the PICU may decrease delirium rates and improve the care we provide to critically ill children.
